Please Wait
Applying Filters...
menu
    • menu
    Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

    Stock Recap
    #PipelineProspector

    Menu

    Cysteamine Bitartrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    30/12/2024 Cambrex Corporation
    U.S.A
    		 Cambrex Profarmaco Milano S. r. l. 225MF10146 Cysteamine bitartrate 2013-07-25 2023-02-15 Via Curiel 34, 20067 Paulo, Milano, ITALY
    30/12/2024 Recordati
    Italy
    		 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S. P. A. 305MF10033 Cysteamine Tartrate 2023-03-15 2023-03-15 VIA M. Civitali, 1-20148 MILANO, ITALY